EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)

Isabel Virchow, Jürgen-Walter Treckmann, Nicole Prasnikar, Gabriele Linden, Peter Markus, Brigitte Schumacher, David Albers, Thomas Herold, Saskia Ting, Hartmut Schmidt, Sonja Radunz, Marcel Wiesweg und 3 weitere

Oncology Research and Treatment · 2023

DOI: 10.1159/000529012 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Oncology Research and Treatment, 2023. Verfasst von Isabel Virchow und 14 weiteren Autor:innen. Beteiligte Einrichtung: West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gemcitabine and cisplatin is the standard first-line systemic treatment in patients with advanced cholangiocarcinoma (CCA). However, a substantial number of patients do not qualify for cisplatin due to comorbidities or poor performance status. The phase II pilot study NACHO evaluated the efficacy of nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) given on days 1, 8, and 15 every 4 weeks as first-line therapy in patients with advanced CCA ineligible for cisplatin-based chemotherapy.

Methods

Patients with any comorbidity precluding cisplatin therapy, such as renal impairment, impaired hearing, increased risk or history for thromboembolic events, intolerance of extensive hydration, or significant cardiovascular disease were eligible. Primary endpoint was overall response rate (ORR) per RECIST 1.1. Secondary endpoints were progression-free survival (PFS), overall survival (OS), safety, and patient reported outcome.

Results

From December 2016 to July 2017, 10 patients were prospectively enrolled and treated. The ORR with nab-paclitaxel/gemcitabine was 50%, the disease control rate (DCR) was 90%. Median PFS was 5.7 months (95% CI: 5.3–6.1), and median OS was 7.8 months (95% CI: 5.4–10.2). In total, 13 SAEs were documented without any new safety signals. There were 14 grade 3–4 treatment-related adverse events (TRAEs) in 10 patients of the ITT population. Exploratory subgroup analyses including known prognostic markers were performed.

Conclusions

The NACHO trial supports safety and efficacy of nab-paclitaxel and gemcitabine in patients with advanced CCA ineligible for cisplatin-based therapy and should be further evaluated in a larger prospective trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsPancreatic NeoplasmsHumansGemcitabineCisplatinDeoxycytidinePilot ProjectsProspective StudiesAntineoplastic Combined Chemotherapy ProtocolsPaclitaxelAlbuminsBile Ducts, IntrahepaticTreatment Outcome

Stichwörter der Autor:innen

CholangiocarcinomaCisplatin ineligibilityGemcitabineNab-paclitaxelSystemic chemotherapy

Substanzen

Gemcitabine130-nm albumin-bound paclitaxelCisplatinDeoxycytidinePaclitaxelAlbumins

Autor:innen und Institutionen

  • West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany.
  • Medical Faculty, University Duisburg-Essen, Essen, Germany.
  • West German Cancer Center, Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany.
  • Ambulatory Health Care Center for Haematology and Medical Oncology, Hamburg, Germany.
  • Department of General, Visceral and Trauma Surgery, Elisabeth Hospital Essen, Essen, Germany.
  • Department of Gastroenterology, Elisabeth Hospital Essen, Essen, Germany.

Zitieren

APA

Virchow, I., Treckmann, J. W., Prasnikar, N., Linden, G., Markus, P., Schumacher, B., Albers, D., Herold, T., Ting, S., Schmidt, H., Radunz, S., Wiesweg, M., Siveke, J., Schuler, M., & Kasper, S. (2023). A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO). Oncology Research and Treatment. https://doi.org/10.1159/000529012

Vancouver

Virchow I, Treckmann JW, Prasnikar N, Linden G, Markus P, Schumacher B, et al. A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO). Oncology Research and Treatment. 2023. doi:10.1159/000529012

BibTeX
@article{Virchow2023,
  author = {Virchow, Isabel and Treckmann, Jürgen-Walter and Prasnikar, Nicole and Linden, Gabriele and Markus, Peter and Schumacher, Brigitte and Albers, David and Herold, Thomas and Ting, Saskia and Schmidt, Hartmut and Radunz, Sonja and Wiesweg, Marcel and Siveke, Jens and Schuler, Martin and Kasper, Stefan},
  title = {A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)},
  journal = {Oncology Research and Treatment},
  year = {2023},
  doi = {10.1159/000529012}
}
Kostenlos starten →